HDAC6-IN-13

• CAT Number: I042830
• CAS Number: 2837128-41-1
• Molecular Formula: C23H22N4O
• Molecular Weight: 370.45
• Purity: ≥95%
• Synonyms: N’-ethyl-4-(pyrido[3,4-b][1]benzazepin-11-ylmethyl)benzohydrazide
• IUPAC Name: N'-ethyl-4-(pyrido[3,4-b][1]benzazepin-11-ylmethyl)benzohydrazide
• InChI: InChI=1S/C23H22N4O/c1-2-25-26-23(28)20-9-7-17(8-10-20)16-27-21-6-4-3-5-18(21)11-12-19-13-14-24-15-22(19)27/h3-15,25H,2,16H2,1H3,(H,26,28)
• InChIKey: ZNRZSMMDQXGEGA-UHFFFAOYSA-N
• SMILES: CCNNC(=O)C1=CC=C(C=C1)CN2C3=CC=CC=C3C=CC4=C2C=NC=C4

HDAC6-IN-13（Cat No.:I042830）is a small molecule inhibitor designed to selectively target and inhibit HDAC6, a member of the histone deacetylase family. HDAC6 plays a critical role in regulating cellular processes such as protein degradation, cell migration, and stress response. By inhibiting HDAC6, HDAC6-IN-13 aims to alter cellular signaling pathways, offering potential therapeutic benefits in cancer, neurodegenerative diseases, and inflammation. Preclinical studies suggest that HDAC6-IN-13 may enhance protein quality control and reduce neuroinflammation, showing promise for treating conditions like Alzheimer’s and Parkinson’s disease. Ongoing research focuses on its efficacy and safety in clinical applications.